Company Filing History:
Years Active: 2002-2006
Title: Mark Mattencci: Innovator in Oligomer Technology
Introduction
Mark Mattencci is a notable inventor based in Burlingame, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of novel oligomers. With a total of 2 patents, Mattencci's work focuses on enhancing the formation of duplexes and triplexes, which has important implications for medical applications.
Latest Patents
Mattencci's latest patents include innovations related to enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines. These novel oligomers exhibit an improved ability to form duplexes or triplexes compared to those containing only conventional bases. The oligomers incorporate bases such as 5-(1-propynyl)uracil and 5-(1-propynyl)cytosine, which allow them to form triplexes with various target sequences, including those associated with viruses or oncogenes. This technology can be utilized in pharmaceutical applications to treat diseases caused by viruses and for diagnostic purposes.
Career Highlights
Mark Mattencci is currently associated with Isis Pharmaceuticals, Inc., where he continues to advance his research in oligomer technology. His work has the potential to revolutionize the way certain diseases are treated and diagnosed, showcasing his commitment to innovation in the field.
Collaborations
Some of Mattencci's notable coworkers include Brian C Froehler and Rick Wagner, who contribute to the collaborative environment that fosters innovation at Isis Pharmaceuticals.
Conclusion
Mark Mattencci's contributions to the field of biotechnology through his patents and work at Isis Pharmaceuticals highlight his role as a key innovator. His research on oligomers has the potential to significantly impact medical treatments and diagnostics.